Oncolytic virotherapy in 2026: overview
Oncolytic virotherapy uses viruses that preferentially infect and destroy cancer cells. The resulting cell damage can also expose tumor antigens and stimulate an antitumor immune response, making these viruses both direct therapies and potential immune primers. The central challenge is to deliver enough virus into tumors, sustain activity despite antiviral defenses, and spare healthy tissue. That challenge is driving work on engineered viruses, immune-modulating payloads and combinations with other cancer treatments.
Recent work is pushing beyond tumor-cell lysis toward immune remodeling and targeted delivery. In September 2026, Xiamen University researchers reported a modular oncolytic herpesvirus designed to re-educate tumor-associated macrophages; another September publication described mast cells ferrying viruses into tumors. Oncolytics Biotech reported preclinical pelareorep activity alongside a pan-RAS inhibitor in October 2026. Meanwhile, Replimune received FDA accelerated approval for Tudriqev for advanced melanoma in August 2026, adding a clinical milestone as researchers test new combinations and delivery strategies.
- 1Immune engineering expands: September 2026 studies from Xiamen University and Jinan University point to engineered viruses and carrier cells that can reshape tumor immunity or improve delivery.
- 2Combination strategies advance: Oncolytics Biotech’s October 2026 preclinical results support testing pelareorep alongside pan-RAS inhibition, while clinical research continues to pair viruses with immunotherapies.
- 3Patents cool, research persists: Patent activity fell 57.9% while publications declined 2.7%, suggesting a sharper slowdown in patenting than in research output.
Top organizations working on oncolytic virotherapy
Ranked by Linknovate activity score · last 24 monthsThe activity score adds up the relevance of every patent, publication, grant and news item linking an organization to oncolytic virotherapy. Showing 7 of 1,182 organizations.
| # | Organization | Approach | Signals (24 mo) | Momentum | Why it matters |
|---|---|---|---|---|---|
| 1 | 
Merck And Co.
Corporate · United States |
Herpes simplex virus | PAT 1 · PUB 7 NEWS 173 |
-69% | Talimogene laherparepvec (T-VEC), an oncolytic herpes simplex virus, has been studied with pembrolizumab in patients with advanced solid tumors and liver metastases. |
| 2 | 
Amgen Inc.
Corporate · United States |
Herpes simplex virus | PAT 3 · PUB 3 NEWS 113 |
-72% | It develops talimogene laherparepvec (T-VEC), an approved oncolytic herpesvirus, and has characterized its clinical pharmacology in adult and pediatric patients. |
| 3 | 
Oncolytics Biotech
Corporate · Canada |
Reovirus platforms | PUB 6 · NEWS 52 | +32% | Recently, it reported preclinical findings that pelareorep retained activity alongside a pan-RAS inhibitor and published evidence of immune responses in liver cancer that may support immunotherapy. |
| 4 | 
Genelux Corporation
Corporate · United States |
Poxvirus platforms | PUB 4 · NEWS 55 | -45% | Recently, Genelux reported a small-cell lung cancer case with a durable response following Olvi-Vec, its oncolytic vaccinia virus, and platinum rechallenge. |
| 5 | 
University of Texas M. D. Anderson Cancer Center
Research · United States |
Herpes simplex virus | PUB 34 · NEWS 27 | +82% | Researchers at the cancer center study oncolytic herpesvirus treatment, including T-VEC for advanced nonmelanoma skin cancers and interactions between oncolytic HSV and cancer drugs. |
| 6 | 
Lokon Pharma AB
Startup · Sweden |
Adenovirus platforms | PUB 1 · NEWS 35 | -62% | It develops LOAd, an oncolytic adenovirus platform for cancer immunotherapy. |
| 7 | 
Sun Yat Sen University
Research · China |
Other RNA virus platforms | PAT 1 · PUB 44 | +65% | Researchers investigate oncolytic virus strategies including M1-based therapy and engineered viruses that activate antitumor immunity, as well as approaches to improve tumor delivery. |
| 8 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 9 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 10 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
Startups to watch and leading research centers
Startups to watch 22 total
TILT Biotherapeutics LtdFinlandIt develops TILT-123, an oncolytic adenovirus that produces cytokines and is being evaluated with tumor-infiltrating lymphocytes for metastatic melanoma.
Gene Medicine Inc.United StatesIt is a clinical-stage biopharmaceutical developer of viral immunotherapies, including candidates for cancer treatment.
VyriadUnited KingdomIt develops viral cancer therapies and holds patent claims covering the use of oncolytic viruses to treat cancer.- ··Hidden startupCountryAvailable to registered users, with funding and founding year.
- ··Hidden startupCountryAvailable to registered users, with funding and founding year.
Leading research institutions 1,020 total
- Sun Yat Sen UniversityChinaResearchers investigate oncolytic virus strategies including M1-based therapy and engineered viruses that activate antitumor immunity, as well as approaches to improve tumor delivery.
- University of Texas M. D. Anderson Cancer CenterUnited StatesResearchers at the cancer center study oncolytic herpesvirus treatment, including T-VEC for advanced nonmelanoma skin cancers and interactions between oncolytic HSV and cancer drugs.
- ZSZhejiang Sci-Tech UniversityChinaRecently, researchers reported GC001, a vaccinia virus engineered to express STRIP1 shRNA, and its entry into clinical development in China.
- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
Where oncolytic virotherapy innovation happens
Share of documents with at least one organization from each country.
Open the interactive map with all 1,182 organizationsMain technical approaches
Last 24 months| Approach | What it is | Documents | Leading organizations |
|---|---|---|---|
| Adenovirus platforms | Adenoviruses can be engineered to replicate in tumors or deliver immune-stimulating payloads; pre-existing immunity and limited tumor penetration can constrain treatment. | 635 |
Genesis, U.S. Food and Drug Administration, Merck And Co. |
| Herpes simplex virus | Herpes simplex viruses support local tumor killing and immune activation, but intratumoral delivery and antiviral safety management can limit use. | 575 |
U.S. Food and Drug Administration, Genesis, Amgen Inc. |
| Poxvirus platforms | Poxviruses can carry substantial genetic payloads and spread through tumors, while systemic delivery and immune clearance remain important hurdles. | 309 |
Genesis, U.S. Food and Drug Administration, Genelux Corporation |
| Reovirus platforms | Reoviruses can exploit tumor-cell signaling vulnerabilities and stimulate immunity, but variable tumor susceptibility can make responses difficult to predict. | 191 |
Oncolytics Biotech, Genesis, U.S. Food and Drug Administration |
| Other RNA virus platforms | Other RNA viruses offer distinct tumor tropisms and immune effects, but each platform brings its own safety, delivery and manufacturing challenges. | 305 |
Merck And Co., U.S. Food and Drug Administration, Genesis |
Emerging trends
Last 12 months vs previous 36 monthsTerms whose frequency in the last 12 months grew the most compared with the previous 36 months.
Funding and investment
Recent funding rounds
Recorded grants total $19,411,812 across 21 awards since 2020. The funding-round entries include unrelated deals, so they are not a reliable measure of investment in oncolytic virotherapy.
Patent landscape
Top patent holders · last 24 monthsRecent developments
Latest news, duplicates removed- Oct 2026Preclinical results demonstrate pelareorep activity is maintained in the presence of RAS inhibition Findings support further evaluation of pelareorep’s potential to deepen and prolong responses to RAS-targeted therapy…GlobeNewswire - News from California
- Oct 2026Dublin, Aug. 10, 2026 (GLOBE NEWSWIRE) -- The "America Cancer Immunotherapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.…GlobeNewswire - Industry News on Industrials
- Oct 2026Newswise — Leor Weinberger, Ph.D., virologist and professor with Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has been awarded the National Institutes of Health (NIH)…Newswise: MedNews
- Sep 2026SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced data published in the…GlobeNewswire: Health
- Month 20XXHidden developmentAvailable to registered users with alerts enabled.
Frequently asked questions about oncolytic virotherapy
What companies are working on oncolytic virotherapy?
Merck And Co. (181 recent-window documents), Amgen Inc. (120), Oncolytics Biotech (58) and Genelux Corporation (59) are prominent company actors. Merck And Co. and Amgen develop talimogene laherparepvec, while Oncolytics Biotech develops pelareorep and Genelux develops the oncolytic vaccinia virus Olvi-Vec. These companies represent herpesvirus, reovirus and poxvirus approaches.
Which oncolytic virotherapy startups are notable in 2026?
TILT Biotherapeutics Ltd (41 recent-window documents), Vyriad (13) and Gene Medicine Inc. (9) are startups active in the field. TILT develops TILT-123, an adenovirus that produces cytokines and is being evaluated with tumor-infiltrating lymphocytes. Vyriad develops viral cancer therapies, while Gene Medicine develops viral immunotherapies, including cancer candidates.
Which universities and research centers lead oncolytic virotherapy research?
Sun Yat Sen University (45 recent-window documents), the University of Texas M. D. Anderson Cancer Center (62) and Zhejiang Sci-Tech University (36) are among the active research organizations. Their work includes M1-based and immune-activating virus strategies, oncolytic herpesvirus treatment, and GC001, an engineered vaccinia virus reported to have entered clinical development in China.
How much funding has oncolytic virotherapy received?
The recorded grant total is $19,411,812 across 21 grants since 2020. This is the grant funding listed for the topic, not a complete estimate of all investment in companies or product development. Funding-round records include deals that do not appear relevant to oncolytic virotherapy, so they should not be treated as a topic-wide investment total.
Who holds the most oncolytic virotherapy patents?
Regeneron Pharmaceuticals Inc. leads the listed patent holders with 14 patents, followed by Joint Biosciences Sh Ltd. with 13. CG Oncology Inc. holds 7, City of Hope holds 6, and the University Of Pittsburg Of The Commonwealth System Of Higher Education holds 5. The listed counts identify patent holders; they do not indicate the commercial status of each patent.
Is oncolytic virotherapy patent activity growing?
No: patent activity declined 57.9% in the last 12 months compared with the previous 12 months, with 253 patents recorded in the 24-month window. Publication activity was more stable, declining 2.7% in the last 12 months. These figures show a sharper recent contraction in patenting than in research publications.
How mature is oncolytic virotherapy?
The field has approved therapies and active clinical development, including Amgen’s talimogene laherparepvec and Replimune’s Tudriqev, which received FDA accelerated approval for advanced melanoma in August 2026. At the same time, research on engineered viruses, tumor delivery and treatment combinations shows that broader use still depends on improving efficacy and overcoming delivery and immune-response barriers.
What are the main approaches in oncolytic virotherapy and how do they differ?
The main platform groups are adenovirus, herpes simplex virus, poxvirus, reovirus and other RNA virus platforms. They differ in tumor tropism, genetic payload capacity, immune effects and delivery characteristics. For example, TILT-123 is an adenovirus designed to produce cytokines, while Olvi-Vec is an oncolytic vaccinia virus. Each platform must balance tumor activity with safety and delivery constraints.
What are the applications of oncolytic virotherapy?
The listed applications include brain tumors (590 documents), colorectal cancer (407), liver cancer (292), ovarian cancer (274), melanoma (182) and hematologic cancers (176). These counts indicate areas of documented activity, not proof that a therapy is effective for every cancer type. Research and development also span solid tumors and disease-specific combinations with immunotherapies or other treatments.